AstraZeneca Pharma India Limited announced its second quarter (July-September 2026) financial results, reporting a significant 30% growth in revenue from operations, reaching INR 7,291 million. The company also achieved a 30% growth in its first half (April-September 2026) revenue, totaling INR 14,119 million. Three new regulatory approvals were secured in Q2, reinforcing its leadership in key therapy areas, including Oncology, Biopharmaceuticals, and Rare Diseases.
AstraZeneca Pharma India Reports Strong Q2 Performance
AstraZeneca Pharma India Limited has announced its financial results for the second quarter and first half of the fiscal year 2026-27. The company demonstrated robust growth, with total revenue from operations reaching INR 7,291 million for the second quarter (July-September 2026), marking a 30% increase compared to the same period last year.
First Half Revenue Surges 30%
For the first half of the fiscal year 2026-27 (April-September 2026), AstraZeneca Pharma India’s total revenue from operations stood at INR 14,119 million, also reflecting a substantial 30% growth over the previous financial year. This performance is attributed to disciplined execution, strong operational efficiency, continued portfolio expansion, and the increasing adoption of innovative therapies.
Key Therapy Area Performance
The growth was consistent across the company’s primary therapy areas:
- Oncology: Reported revenue of INR 5,085 million in Q2 2026-27 and INR 9,733 million in H1 2026-27.
- Biopharmaceuticals (CVRM, R&I and V&I): Achieved revenue of INR 1,610 million in Q2 2026-27 and INR 3,229 million in H1 2026-27.
- Rare Diseases: Recorded revenue of INR 204 million in Q2 2026-27 and INR 347 million in H1 2026-27.
New Regulatory Approvals
In the second quarter, AstraZeneca Pharma India secured three new regulatory approvals, further solidifying its leadership across critical therapy areas. These approvals include:
- Trastuzumab deruxtecan: Received regulatory approval for multiple indications related to HER2-positive early and metastatic breast cancer.
- Benralizumab: Received regulatory approval for the treatment of hypereosinophilic syndrome in patients aged 12 years and older.
- Acalabrutinib: Received regulatory approval for chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) in combination therapies, and for mantle cell lymphoma (MCL).
Strategic Initiatives and Recognitions
The company also highlighted its ongoing strategic initiatives, including MoUs with the states of Andhra Pradesh and Telangana for advancing oncology care and lung cancer screening respectively. Furthermore, ‘K+ Connect’ was launched to improve hyperkalaemia management, and ‘India Coronary Conquest 2026’ was initiated to advance cardiovascular care. AstraZeneca Pharma India also received accolades, including the Medical Excellence Award for its contributions to Rare Disease at the OPPI India Awards 2026.
Source: BSE
